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Abstract
Background: Late onset sepsis (LOS) in preterm infants is associated with considerable morbidity and mortality.
While studies have implicated gut bacteria in the aetiology of the disease, functional analysis and mechanistic
insights are generally lacking. We performed temporal bacterial (n = 613) and metabolomic (n = 63) profiling on
extensively sampled stool from 7 infants with LOS and 28 matched healthy (no LOS or NEC) controls.
Results: The bacteria isolated in diagnostic blood culture usually corresponded to the dominant bacterial genera in
the gut microbiome. Longitudinal changes were monitored based on preterm gut community types (PGCTs),
where control infants had an increased number of PGCTs compared to LOS infants (P = 0.011). PGCT 6,
characterised by Bifidobacteria dominance, was only present in control infants. Metabolite profiles differed between
LOS and control infants at diagnosis and 7 days later, but not 7 days prior to diagnosis. Bifidobacteria was positively
correlated with control metabolites, including raffinose, sucrose, and acetic acid.
Conclusions: Using multi-omic analysis, we show that the gut microbiome is involved in the pathogenesis of LOS.
While the causative agent of LOS varies, it is usually abundant in the gut. Bifidobacteria dominance was associated
with control infants, and the presence of this organism may directly protect, or act as a marker for protection,
against gut epithelial translocation. While the metabolomic data is preliminary, the findings support that gut
development and protection in preterm infants is associated with increased in prebiotic oligosaccharides (e.g.
raffinose) and the growth of beneficial bacteria (e.g. Bifidobacterium).
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Background
Late onset sepsis (LOS; defined as sepsis after 72 h of life)
remains a serious and common complication of prematurity,
with rates of 20–40% for infants <32 weeks gestation re-
ported in some studies. LOS in preterm infants impacts
negatively on survival (with mortality rates of up to 10%)
and on developmental outcomes [1]. Mechanisms of LOS
pathogenesis are poorly understood, but bacterial colonisa-
tion and low gestational age are key risk factors [2]. Bacterial
profiling studies have shown that LOS infants have an al-
tered microbiome and lower bacterial diversity [3–8], and
the bacterial strain isolated in diagnostic blood culture is fre-
quently present in the gut [9]. Central to LOS pathogenesis
are bacterial-host interactions modulating gut and systemic
immune responses, tight junction integrity, and host meta-
bolic function [10]. The most common organisms causing
LOS in preterm infants include coagulase-negative Staphylo-
coccus, Escherichia, Klebsiella, and Enterococcus [11].
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Recent advances in ultra-performance liquid chromato
graphy-mass spectrometry (UPLC-MS) untargeted meta-
bolomics facilitate further understanding of these com-
plex relationships involving host and bacteria, and the
complex interactions of immune and metabolic function
in relation to health and disease states [12]. While
largely pilot in nature, existing metabolomic studies in
preterm infants have demonstrated important findings.
In necrotizing enterocolitis (NEC), the most prevalent
serious preterm disease after LOS, the metabolite pro-
files are different at diagnosis compared to controls in
serum [13–15], urine [16], and stool [17]. Stool volatile or-
ganic compound and serum UPLC-MS has also demon-
strated differences between LOS infants and matched
controls at or immediately prior to disease [13, 15, 18].
Stool metabolite profiles are also significantly associated
with age [19] and serum metabolite profiles between pre-
term and term neonates also differ [14].
We aimed to explore relationships between gut micro-
biome and metabolome to determine key insights into
LOS development, impact, and recovery. This is the first
study to employ UPLC-MS untargeted metabolomics of
stool to determine host and bacterial functioning within
the gut of infants diagnosed with LOS.
Results
Infant and sample information
We recruited a large cohort of preterm infants, sampling
stool daily where possible (n = >300 infants/>3000 sam-
ples) and capturing key health-related outcomes using
precise definitions [17, 20, 21]. Using strict classification
for LOS (positive blood culture with a >5 days antibiotics)
and only including infants with robust temporal sampling
before and after disease diagnosis, we present comprehen-
sive longitudinal gut microbiome data on 613 stool sam-
ples from LOS infants (n = 7) and well-matched non-
diseased (no NEC or LOS) controls (n = 28). A subset of
63 stool samples from LOS infants (n = 4) and matched
controls (n = 10) also underwent UPLC-MS.
Infant demographics are shown in Table 1 and further
detail provided in Additional file 1: Table S1. The
average number of samples for LOS and control infants
was comparable (15 vs. 18, respectively). Infant demo-
graphics were comparable between LOS and matched
controls, although as expected, antibiotic use was in-
creased in LOS (antibiotic information provided in
Additional file 2: Table S2). Diagnostic blood culture
identified two cases of Staphylococcus aureus, two cases
of Staphylococcus epidermidis, one case of Enterococcus
faecalis, one case of Streptococcus agalactiae, and one
case of Escherichia coli (Additional file 1: Table S1).
The abundant bacterial genus in the gut microbiome
preceding diagnosis corresponds to the genera of the
causative agent in LOS
The gut microbiome of infants with LOS were highly in-
dividual and dynamic through time. The pathogen iden-
tified by blood culture was one of the most abundant
OTUs in the gut microbiota at diagnosis, with the corre-
sponding genus from the gut microbiome the most
abundant in four cases and second most abundant OTU
in two cases (Fig. 1). An exception was Staphylococcus
epidermidis LOS in infant 251, which was the seventh
most abundant genus at diagnosis. In all cases, the gen-
era of the bacteria isolated in diagnostic blood culture
were present prior to LOS diagnosis. For infant 173 who
was diagnosed with S. agalactiae, the organism was de-
tected 2 days before diagnosis and within 6 days of anti-
biotic treatment (flucloxacillin and gentamicin) it was no
longer detected.
Preterm gut community types dominant in
Bifidobacterium are protective for LOS
To further explore the complexity in the developing pre-
term microbiome, we employed PAM clustering analysis
to ascertain preterm gut community types (PGCTs), as
previously described [17]. All samples grouped into six
discrete clusters (Additional file 3: Figure S1): dominance
of Klebsiella (PGCT 1), dominance of both Klebsiella and
Enterococcus (PGCT 2), dominance of Staphylococcus
(PGCT 3), dominance of Enterococcus (PGCT 4), domin-
ance of Escherichia (PGCT 5), and mixed population with
Table 1 Summary of infant samples and demographic per group
Control (n = 28) LOS (n = 7) P value
Number of stool samples 520 106 –
Gestation (weeks)* 27 (25–28) 27 (26.5–28) 0.393
Birth weight (g)* 910 (863–1199) 1000 (725–1105) 0.612
Birth mode (CS/vaginal) 12/16 3/4 1.0
Gender (male/female) 20/8 4/3 0.475
Breast milk exposure (yes/no) 25/3 7/0 0.820
Antibiotic prediagnosis (days)* – 7 (2–14) –
Antibiotic total (days)* 4.5 (2–9.5) 23 (10–32) 0.071
*Median (interquartile range)
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high relative abundance of Bifidobacterium (PGCT 6)
(Additional file 4: Figure S2). No PGCT was strongly asso-
ciated with PreLOS samples when compared to all control
samples, whereas PGCT 2 and PGCT 6 were never found
in any sample from LOS infants before diagnosis (Fig. 2a).
PGCT 6 was also never found in any LOS infant after
diagnosis, and PGCT 2 was present in only 2 infants after
diagnosis, detected >2 weeks following diagnosis and
treatment (Fig. 2b and Additional file 4: Figure S2). Con-
versely PGCT 6, which represents a diverse community
high in relative Bifidobacterium abundance, was present
frequently throughout the control population from early
to late samples. Specifically, PGCT 6 was detected in 65
samples from 12 control infants, representing 43% of the
control population. Counting the number of unique
PGCTs over the first 25 days of life showed control infants
had an average of 3 unique PGCTs, compared to an aver-
age of 2 unique PGCTs in preLOS samples (P = 0.011).
Untargeted metabolomic profiling indicates distinct
functional profiles between infants with LOS and controls
Given the finding that the dominant genus in the micro-
biome is associated with the causative agent in LOS, we
further investigated the potential functional differences
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Fig. 1 Area plots showing the temporal development of the microbiome in infants diagnosed with late onset sepsis (LOS). Dashed red lines
represent the day of LOS diagnosis with the bacteria isolated from blood culture identified. Dashed black lines represent the start of an antibiotic
treatment as per Additional file 2: Table S2.
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in the gut between infants diagnosed with LOS and
matched controls. Due to sample availability, this pilot
experiment included 4 infants with LOS (infants 130,
172, 181, and 251) and 10 matched controls, across 5
time points spanning before and after LOS diagnosis:
−14 days (time point 1; TP1), −7 days (TP2), 0 days
(TP3), +7 days (TP4), and +14 days (TP3), relative to
diagnosis of LOS. Although each LOS infant had differ-
ent bacterial species isolated in diagnostic blood culture
(Fig. 1), PCA showed metabolite profiles clustering dis-
tinctly between LOS infants and matched controls, with
the most profound differences at diagnosis (0 days) and
+7 days (Fig. 3). Receivers operating characteristic
(ROC) curves were generated, and area under a ROC
curve (AUC) was implemented to provide a measure of
how well metabolites distinguish between LOS and
matched controls. Lines progressing towards the upper-
left corner of plots represent better discrimination
(higher sensitivity and specificity). At diagnosis, the
AUC ranged from 0.787 with 5 metabolites to 0.883 with
25 metabolites and both equated to a sensitivity of 75%
and a specificity of 89%.
Fourteen stool metabolites were identified as signifi-
cantly altered between LOS and control infants at diag-
nosis (TP3), with 7 metabolites (all increased in
controls) remaining significant following adjustment for
7 confounders (Table 2). Galactose metabolism was the
most frequently increased pathway in control infants,
and sucrose (P = 0.001) and raffinose (P = 0.001), both
from galactose metabolism, were the most significant
metabolites. These metabolites increased through time
within control infants, whereas the same metabolites
remained at baseline or reduced prior to diagnosis in
LOS infants (Fig. 4). Notably, following diagnosis and
treatment, these metabolites increased in LOS infants,
but tended to remain at lower intensity compared to
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Fig. 2 Characterisation of the gut microbiome between infants diagnosed with late onset sepsis (LOS) and matched controls. a Transition network
analysis showing PGCTs in PreLOS samples compared to matched controls approximated as a Markov chain with subject-independent transition
probabilities. Arrow weights reflect the transition probabilities from one sample to the next. Size of circle reflects the relative number of samples
associated with that PGCT. Pale blue indicates PGCTs of consisting of control samples only, and the darker shade of purple shows increased number of
PreLOS samples in that PGCT. b Temporal change in PGCTs in each individual infant. Red lines represent day of LOS diagnosis. Only samples up to day
50 of life are included. Infant 178 died during the study
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controls (with the exception of metabolites from C21-
steroid hormone biosynthesis that remained at baseline
throughout). Taken together, the PCA and box plot ana-
lysis of the most significant metabolites suggest altered
and delayed functional development in the gut in LOS
infants prior to diagnosis.
Multi-omic analysis shows distinct correlations between
significant metabolites and abundant bacterial genera
sPLS correlation analysis was performed using MixO-
mics to determine the correlations between the domin-
ant bacterial genera and identified metabolites (Fig. 5).
Bifidobacterium and Streptococcus showed comparable
strong positive correlations with a range of metabolites
that were significantly increased in control infants
(Table 2), including raffinose, 18-hydroxycortisol, 18-
oxocortisol, acetic acid, and L-alpha-acetyl-N-normetha-
dol. These findings were supported when only including
control infants in the analysis; demonstrating diagnosis is
not confounding the results (Additional file 5: Figure S3).
Furthermore, this correlation was lost when analysing a
shuffled dataset and is thus not an artifact of autocorrel-
ation. Morganella also showed weak positive correlation
with these metabolites. Veillonella showed distinct cluster-
ing with strong correlations to a range of metabolites, in-
cluding vitamin K and ascorbic acid (vitamin C), as well as
10,11-dihydro-12R-hydroxy-leukotriene E4 that was sig-
nificantly increased (P = 0.032) in LOS infants. Staphylo-
coccus, Bacteroides, Escherichia, Klebsiella, Enterococcus,
and Pseudomonas all showed weak correlations with the
detected metabolites.
Discussion
We explored gut microbiome and metabolome factors
that are altered in the development of LOS in preterm
infants and show that the dominant taxa in the gut
microbiome are usually isolated in diagnostic blood cul-
ture. Control infants had greater microbiome develop-
ment and prevalence of PGCT 6 (Bifidobacterium
dominant). Novel untargeted stool metabolomics on a
subset of samples showed that metabolite profiles are
significantly different between LOS and control infants
at diagnosis and 7 days later. Stool metabolites from a
range of pathways/sources, especially sucrose and
A B Fig. 3 Metabolomic profiles between infants diagnosed with LOS and
matched controls across all 5 time points, where TP3 represents
samples at diagnosis. a PCA (unconstrained ordination) of LOS infants
(red) and matched controls (green). Each sample represented by the
small circle and ellipses represent the 95% confidence interval. b
Receiver operating characteristic curves of support vector machine
predictions for LOS and control samples. AUC represents the strength
of the predictive classifications. Selected number of metabolites
computed in intervals from 5, 10, 15, 25, 50, and 100 metabolites
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Table 2 List of metabolites and pathways significantly altered between control and LOS infants at diagnosis (day 0)
Metabolite Pathway Fold change Log2(FC) P value Adjusted
P value
Increased in controls Sucrose Galactose metabolism 15.6 3.96 0.001 0.005
Raffinose Galactose metabolism 1963.1 10.94 0.001 0.014
18-Hydroxycortisol C21-steroid hormone biosynthesis
and metabolism
10683 13.38 0.003 0.010
L-Glutamate Tryptophan metabolism 29.33 4.87 0.003 0.008
18-Oxocortisol C21-steroid hormone biosynthesis
and metabolism
17551 14.10 0.005 0.013
Didemethylcitalopram N-Glycan degradation 6.14 2.62 0.007 0.021
L-alpha-Acetyl-N-normethadol Drug metabolism-cytochrome P450 676.77 9.40 0.009 0.226
Acetic acid C21-steroid hormone biosynthesis
and metabolism
577.12 9.17 0.011 0.042
Lactose Galactose metabolism 11.66 3.54 0.033 0.123
3-Ketolactose Galactose metabolism 555.27 9.12 0.047 0.002
Increased in LOS 21-Hydroxy-5beta-pregnane-3,11,20-trione C21-steroid hormone biosynthesis
and metabolism
0.004 −7.93 0.034 0.137
10,11-dihydro-leukotriene B4 Leukotriene metabolism 0.16 −2.68 0.034 0.153
Monoethylglycinexylidide Drug metabolism-cytochrome P450 0.29 −1.79 0.039 0.125
11-Deoxycortisol C21-steroid hormone biosynthesis
and metabolism
0.004 −7.93 0.043 0.147
Abbreviations: LOS late onset sepsis, FC fold change
A B C D
E F G H
Fig. 4 Box plots to show the levels of significant metabolites though each time point between infants diagnosed with late onset sepsis (LOS)
and matched controls. Plots listed in order of significance. a Sucrose. b Raffinose. c L-Glutamate. d Didemethylcitalopram. e Acetic acid.
f 18-Hydroxycortisol. g 18-Oxocortisol. h L-alpha-Acetyl-N-normethadol
Stewart et al. Microbiome  (2017) 5:75 Page 6 of 11
raffinose, tended to increase in controls through time
compared to LOS infants, where they remained low prior
to and at diagnosis. Finally, combining omic datasets to
explore correlations between the microbiome and metab-
olome showed Bifidobacterium was positively correlated
with metabolites significantly increased in control infants.
The gut microbiome has been previously implicated in
the pathogenesis of LOS [3–9], with whole genome shot-
gun sequencing revealing the exact strain in diagnostic
blood culture can be detected in stool [9]. Our data
concurs, showing the species cultured from blood was
typically abundant from birth and corresponds to the
most or second most abundant OTU in the gut at diag-
nosis. One exception occurred where the microbiome
was dominated by Klebsiella and Escherichia, but S. epi-
dermidis was isolated in blood culture. Due to the preva-
lence of S. epidermidis on the skin, this organism is a
common contaminant of blood cultures, however, it is
also commonly associated with preterm sepsis [22]. It is
possible that different mechanisms are in action where
LOS results from organisms that typically colonise the
skin, for example, through compromised skin barrier
from venepuncture, heel pricks etc., than where the
mechanism is of translocation of gut bacteria [23].
PGCT 6 (Bifidobacteria dominant) was only found in
control infants, detected in nearly half of all control infants
(43%), but whether this is a cause of gut health or a marker
of gut health is unknown. The potential health-promoting
properties of Bifidobacterium are well reported [24–29].
Although the largest existing probiotic trial of 1315 pre-
term infants found no significant improvement to NEC or
LOS rates using Bifidobacterium breve [30], only specific
species of Bifidobacterium in the preterm gut are able to
utilise human milk oligosaccharides (HMOs): these species
appear to have key roles in establishing the pioneering spe-
cies of the gut [31]. While B. breve produce fucosidases
and sialidases, only Bifidobacterium longum subspecies
infantis are able to digest all HMO structures [32]. The
differences between timing, dose, and most importantly
the Bifidobacterium species/strains used are likely to ac-
count for the inconsistent health benefits between Bifido-
bacterium probiotic studies. In a separate cohort, we have
previously shown that Bifidobacterium bifidum deliber-
ately administered to preterm infants can colonise and
persist in threefold greater relative abundance following
discharge, compared to control infants [33].
Metabolomics was employed to determine if the
changes in gut microbiome were reflected at the
Escherichia11beta,21-Dihydroxy-5beta
-pregnane-3,20-dione
Klebsiella
18-Hydroxycortisol
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Fig. 5 Spares partial least squared correlations (sPLS) between dominant bacterial genera and identified metabolites. sPLS in regression mode
(predict Y from X) to model a causal relationship between bacterial genera and metabolites. Bacterial genera represented in green boxes. Red
boxes are metabolites significantly increased in LOS, blue boxed significantly increased in controls, yellow boxes are not significantly altered
between LOS and controls. Significant metabolites based on the samples at diagnosis (time point 0)
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functional level and if metabolic markers for LOS could
be detected. LOS samples grouped distinctly at diagnosis
(sensitivity of 75% and a specificity of 89%). Previous
work has shown serum metabolite profiles [13] and stool
volatile organic compound profiles [18] altered between
LOS infants and controls within 3 days of onset, but no
single metabolite being diagnostic of LOS. We found no
differences in stool metabolites 14 or 7 days before
diagnosis. Although significant in the unadjusted
models, following adjustment for potential confounders,
no metabolite was significantly increased in all LOS in-
fants. This suggests the pathogenesis is of acute onset,
with multiple aetiological components affecting individ-
ual infants differently.
Network analysis was employed to determine correla-
tions between the microbiome and metabolome,
revealing that Bifidobacterium and Streptococcus have
comparable positive correlations. Given Bifidobacterium
dominant communities were specific to control infants
and Bifidobacterium is strongly associated with a healthy
mature gut microbiome [24–29], it is notable that me-
tabolites correlated with this genera were significantly
increased in control infants. Metabolites correlated with
Bifidobacterium and Streptococcus were from a range of
pathways: raffinose (Galactose metabolism), L-alpha-
acetyl-N-normethadol (Drug metabolism), and acetic
acid, 18-hydroxycortisol, and 18-oxocortisol (C21-ster-
oid hormone biosynthesis and metabolism). Raffinose is
a derivative of sucrose, and these two metabolites were
the most significant overall, with both increased in con-
trols. Raffinose is a α-galactosyl (α-GAL) oligosaccharide,
and because humans do not possess the α-GAL enzyme,
it is fermented in the gut by bacteria containing the α-
GAL enzyme. This metabolite reduced in LOS infants
prior to diagnosis, increasing after treatment, whereas it
remained consistently high in controls from day 7 (TP2).
Raffinose is considered a prebiotic [34] that has been
shown to inhibit the growth of potentially pathogenic
bacteria [35] and to promote Bifidobacterium spp. in
human and animal studies [36]. In addition, raffinose
increases short chain fatty acid (SCFA) concentrations,
specifically acetic and propionic acid, contributing to
increased weight gain in animal models [37, 38] and a
reduction in pathogenic bacteria [39]. Due to the use of
LCMS, SCFA were not detected in the current study,
but further work exploring the exact strains of Bifido-
bacterium and their specific effects on the gut
microbiome and metabolome is warranted.
The study has several potential limitations. The strict
inclusion criteria requiring extensive longitudinal sam-
pling before and after disease diagnosis meant only 7
infants with LOS were included, despite collection of
samples from >300 infants. However, this cohort size is
comparable to existing studies in LOS and the findings
here support existing data [3–7, 9]. Cost and sample size
considerations meant metabolomics was performed on
only four infants with LOS and ten controls and thus
conclusions drawn this analysis should be considered
preliminary. It is necessary to repeat the correlation
analysis at specific time windows in larger cohorts.
Nonetheless, this study has yielded important findings
that warrant validation in large multi-center studies with
extensive longitudinal sampling, particularly within
7 days of LOS diagnosis.
Conclusions
Using novel multi-omic analysis, we show for the first
time that the gut microbiome and metabolome are asso-
ciated with the pathogenesis of LOS. In accordance with
published data, we find the causative agent in LOS is
usually abundant in the gut microbiome, suggesting
translocation though the gut epithelium. This is further
supported by the change in bacterial and host metabol-
ism in the gut, which is reflective of altered function.
While the causative agent of LOS varies, Bifidobacteria
dominant communities were only found in controls and
this taxa was further correlated with the metabolites
significantly associated with control infants, including
raffinose, sucrose, and acetic acid. The current study
supports that gut development and protection in
preterm infants is associated with increased in prebiotic
oligosaccharides (e.g. raffinose) and the growth of bene-
ficial bacteria (e.g. Bifidobacterium). The finding in the
current study requires validation in a larger cohort and
the exact mechanisms, and the development of therapies
aimed at promoting health for preterm infants, such as
pre- and probiotics, warrant further investigation.
Methods
Participants and study design
The study design, setting, participants, and methods of data
collection have been reported previously [17, 40]. Briefly, all
infants were cared for in a single unit with standardised
feeding, antibiotic, and antifungal guidelines. LOS was de-
fined as a positive blood culture treated with antibiotics for
a minimum of 5 days along with signs consistent with sep-
sis reviewed independently by two clinicians. Cultured iso-
lates from positive blood culture were identified using
matrix-assisted laser desorption ionisation–time of flight
mass spectrometry. All demographic information is sum-
marised in Table 1, and full information for each infant is
provided in Additional file 1: Table S1.
Stool samples and clinical data were collected from a
total of 318 preterm infants at study conception. Seven
well-sampled cases of LOS and 28 matched controls, free
of LOS, or NEC, were selected based on extensive longitu-
dinal sampling and matched by gestational age (GA;
+/−1 week), birth weight, and delivery mode. A total of
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613 analysed stool samples underwent 16S rRNA gene
bacterial profiling. Metabolomic profiling was performed
on a subset of 14 infants (63 stools): 4 LOS and 10
matched controls. LOS samples were selected for analysis
relative to disease diagnosis at day of life (DOL) −14 (time
point 1; TP1), −7 (TP2), 0 (TP3), +7 (TP4), and +14
(TP5), and controls were matched to this by DOL.
16S rRNA gene bacterial profiling
Nucleic acid extraction of stool was carried out on
100 mg of sample using the PowerLyzer™ PowerSoil®
DNA Isolation Kit (MoBio, CA, USA) in accordance
with the manufacturer’s instructions. Bacterial profiling
utilised the 16S rRNA gene targeting variable region 4
based on the Schloss wet-lab MiSeq SOP and resulting
raw fastq data were processed using Mothur (version
1.31.2), as described previously [41]. Briefly, combined
reads were trimmed to 275 reads with 0 ambiguous
bases. Chimeric sequences were detected by Chimera.u-
chime and were removed from downstream analysis.
Alignment was generated via the Silva v4 database [42]
and chloroplast, mitochondria, unknown, archaea, and
eukaryota linages were removed from the analysis. Raw
sequences were deposited in MG-RAST under the
accession numbers 4516545.3-4516585.3.
UPLC-MS metabolomic profiling
Metabolomic profiling was performed as previously de-
scribed [19, 43]. Briefly, 100 mg stool was homogenised
(80% methanol), was vortexed for 15 min, centrifuged
(10000×g), and was lyophilised. Reverse-phase ultra-
performance LCMS tandem mass-spectrometry (UPLC-
MS/MS) was performed using an Accucore C18 column
(2.6 μm, 150 × 2.1 mm) at 40 °C, 3.0 μl injection, and
300 μl/min flow rate. Gradients increased from 5% acet-
ronitrile (ACN) to 95% ACN over 22 min, followed by
8 min wash, and re-equilibration. Samples were run ran-
domly in triplicate on a Q-Exactive (Thermo) using
HESI with high resolution (70,000) positive and negative
switching. The mass range was set from 100–1000 m/z.
SIEVE (version 2.2) was used to process the Thermo
RAW files by component extraction.
Bioinformatic and statistical analysis
Bacterial community analysis
16S bacterial profiles were analysed using a stand-alone
tool for analysing and visualising microbiome data sets
developed at the Center for Metagenomics and Micro-
biome Research at Baylor College of Medicine (not pub-
lished), conducted in R version 3.3 [44]. Each sample
was rarefied to 4397 reads. PGCTs were determined
using a publically available script for linear mixed-effects
modelling, medoid-based clustering, and Markov chain
modelling [45]. Bray-Curtis was used to calculate the
distance between all samples, and this was denoised by
extraction of the most significant Principal Coordinates
Analysis (PCoA) eigenvectors before applying the PAM
algorithm. Gap statistic was used to determine the num-
ber of clusters. Significance of categorical variables was
determined using the non-parametric Mann-Whitney
test for comparison of LOS and control infants. Only
taxa present in >1% relative abundance were included in
statistical analysis. All P values were adjusted for mul-
tiple comparisons with the false discovery rate (FDR) al-
gorithm [46].
Metabolomics analysis
UPLC-MS data was filtered to include only m/z features
that occurred in >20% of samples. Metabolite annotation
and pathway enrichment was performed using Mummi-
chog [47]. Mummichog was used to determine signifi-
cant pathways between infants diagnosed with LOS and
matched controls. Unlike the microbiome dataset, meta-
bolomics was performed at five specific time windows
relative to LOS onset, with matched day of life control
samples. Analysis was therefore cross sectional within
the specific time windows. Metabolomic MetaboAnalyst
3.0 [48] was employed to generate PCA plots and to de-
termine the AUC between LOS and control infants at
each time point. Receivers operating characteristic
(ROC) curves were generated by linear support vector
machine (SVM) classification with Monte-Carlo cross
validation using balanced subsampling. In each Monte-
Carlo cross validation, two thirds of the samples were
used to examine the feature importance, and the classifi-
cation model was validated using the one third of sam-
ples left out. Several iterations were performed to
determine the optimal number of metabolites to predict
MV use, with analysis based on 5, 10, 15, 25, 50, or 100
of the top metabolites based on the average importance.
Two-tailed Welch’s t test (<2 variables) or ANOVA (>2
variables) were used to determine significant metabo-
lites. Regression models adjusted for seven potential
confounding variables: delivery mode, gestation age, sex,
feed (received some maternal breast milk or formula
only), number of days of antibiotics treatment, number
of antibiotics used, and age. P values were adjusted for
multiple comparisons using FDR [46].
Integrated analysis of microbiome and metabolomic
datasets
MixOmics [49] was implemented in R to determine the
correlation between the relative abundance of the dom-
inant bacterial taxa from 16S rRNA gene sequencing
and the intensity of metabolites of interest by sparse
partial least squares regression (sPLS) [50].
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